health ๐จ B-cell therapies raise major viral disease risks
Patients on modern B-cell-depleting therapies face increased risks of severe arboviral diseases with high mortality. This risk is observed in patients undergoing treatment with anti-CD20 antibodies in various locations. Observational data shows mortality rates near forty percent following neuroinvasive infections in 2026. These immunosuppressive regimens lead to aggressive encephalitis instead of typical mild illness. Clinicians must use molecular testing as standard serology often gives false negatives. ๐ฆ